Prothena Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
40,996.00
7,150.00
80,612.00
160,108.00
153,237.00
155,645
Depreciation, Depletion & Amortization
660.00
743.00
806.00
2,427.00
3,067.00
3,216
Other Funds
84.00
242.00
3,855.00
15,013.00
2,760.00
31,290
Funds from Operations
37,775.00
2,061.00
73,929.00
136,156.00
124,019.00
122,728
Changes in Working Capital
5,677.00
1,378.00
11,474.00
18,887.00
7,164.00
94,452
Net Operating Cash Flow
32,098.00
683.00
62,455.00
117,269.00
131,183.00
28,276
Capital Expenditures
564.00
526.00
1,382.00
16,644.00
3,626.00
Sale of Fixed Assets & Businesses
29.00
27.00
-
-
105.00
Net Investing Cash Flow
535.00
499.00
1,382.00
16,644.00
3,521.00
Net Financing Cash Flow
84,450.00
118,084.00
140,844.00
154,306.00
165,401.00
Net Change in Cash
51,817.00
116,902.00
77,007.00
20,393.00
30,697.00
Free Cash Flow
32,662.00
1,209.00
63,837.00
133,913.00
134,809.00
Deferred Taxes & Investment Tax Credit
538.00
990.00
963.00
3,248.00
2,200.00
1,589
Change in Capital Stock
84,534.00
117,842.00
136,989.00
139,293.00
168,161.00

About Prothena

View Profile
Address
77 Sir John Rogersons Quay
Dun Laoghaire Dublin 2
Ireland
Employees -
Website http://www.prothena.com
Updated 07/08/2019
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. The company was founded on December 20, 2012 and is headquartered in Dun Laoghaire, Ireland.